Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Metastatic colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) molecular phenotypes could significantly benefit from immune checkpoint inhibitor therapy, ushering in the MSI era of immunotherapy for colorectal cancer. However, MSI-H/dMMR is present in only 15%-20% of stage II/III and 5% of stage IV colorectal cancer patients, while the vast majority of patients exhibit microsatellite stability (MSS) or proficient mismatch repair (pMMR) types, which are insensitive to immunotherapy. Therefore, how to enhance the efficacy of immunotherapy in the pMMR/MSS population through combination therapy has become a hotspot and challenge in colorectal cancer research.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony przerzutowy rak jelita grubego
- •Brak poprzedniej chemioterapii, lub przerwa co najmniej 6 miesięcy od ostatniego leczenia
- •Dobry ogólny stan zdrowia (ocena ECOG 0 lub 1)
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Prawidłowe funkcjonowanie wątroby, nerek i szpiku kostnego
- •Dla kobiet: ujemny test ciążowy
- •Dobra wola do udziału w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Nanjing, China
Nanjing First Hospital, Nanjing Medical University Affiliated Hospital
Nanjing, China
Trial contact
Yanhong Gu
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.